Last reviewed · How we verify
Restylane-L®
Restylane-L® is a marketed product developed by the University of Pennsylvania, positioned in the dermatological aesthetics market. The key composition patent expires in 2028, providing a strong barrier to generic competition until then. The primary risk is the lack of revenue data and key trial results, which may limit strategic planning and investor confidence.
At a glance
| Generic name | Restylane-L® |
|---|---|
| Also known as | Hyaluronic acid gel |
| Sponsor | University of Pennsylvania |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- RHA® 3 Versus Restylane-L® for Lip Augmentation
- Prospective Evaluation of Facial Cosmetic Procedures (PHASE4)
- Restylane-L for Correction of Infraorbital Hollows (NA)
- Safety and Effectiveness of STYLAGE® L for Correction of Moderate and Severe Nasolabial Folds in Chinese Adults (NA)
- Effects of Restylane-L® Filler Injection for Non-Surgical Rhinoplasty (PHASE1)
- A Safety and Effectiveness Study of JUVÉDERM VOLBELLA® XC Injectable Gel for Lip and Perioral Enhancement (NA)
- Safety and Effectiveness of Juvéderm® Volbella With Lidocaine Versus Restylane-L® for Lip Volume Enhancement (NA)
- Efficacy and Safety Evaluation Study of Neuramis® Deep Lidocaine in Correction of Nasolabial Fold (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Restylane-L® CI brief — competitive landscape report
- Restylane-L® updates RSS · CI watch RSS
- University of Pennsylvania portfolio CI